Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NVTA, BLFS, FATE, EXAS, BPMC, and represent 43.22% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: EXAS (+$197M), NVTA (+$137M), BLFS (+$64M), BEAM (+$38M), FDMT (+$32M), AGIO (+$27M), CNST (+$23M), MASS (+$23M), ALNY (+$21M), GBT (+$20M).
- Started 11 new stock positions in MASS, SEER, ABCL, FDMT, BEAM, CDAK, SNDX, KRON, CCCC, FHTX. EXAS.
- Reduced shares in these 8 stocks: Myokardia (-$119M), AMRS (-$33M), ILMN (-$9.3M), ORTX (-$7.7M), LEGN, DCPH, FULC, DMTK.
- Sold out of its positions in DCPH, ILMN, LEGN, Myokardia, ORTX.
- Casdin Capital was a net buyer of stock by $507M.
- Casdin Capital has $3.4B in assets under management (AUM), dropping by 51.14%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Companies in the Casdin Capital portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Invitae (NVTA) | 15.2 | $514M | +36% | 12M | 41.81 | |
| Biolife Solutions Com New (BLFS) | 8.8 | $297M | +27% | 7.4M | 39.89 | |
| Fate Therapeutics (FATE) | 8.2 | $277M | 3.1M | 90.93 | ||
| EXACT Sciences Corporation (EXAS) | 5.8 | $197M | NEW | 1.5M | 132.49 | |
| Blueprint Medicines (BPMC) | 5.1 | $174M | 1.6M | 112.15 | ||
| Relay Therapeutics (RLAY) | 4.7 | $158M | 3.8M | 41.56 | ||
| Twist Bioscience Corp (TWST) | 4.2 | $141M | 1.0M | 141.29 | ||
| Pacific Biosciences of California (PACB) | 3.8 | $130M | +11% | 5.0M | 25.94 | |
| Denali Therapeutics (DNLI) | 3.3 | $110M | 1.3M | 83.76 | ||
| Agios Pharmaceuticals (AGIO) | 3.0 | $103M | +35% | 2.4M | 43.33 | |
| Alnylam Pharmaceuticals (ALNY) | 3.0 | $101M | +25% | 780k | 129.97 | |
| Codexis (CDXS) | 2.8 | $95M | +8% | 4.3M | 21.83 | |
| Sarepta Therapeutics (SRPT) | 2.7 | $90M | 530k | 170.49 | ||
| Caredx (CDNA) | 2.6 | $87M | 1.2M | 72.45 | ||
Setup an alertCasdin Capital will file the next quarterly 13-HR in about 1 months. Would you like to be notified? |
||||||
| Revolution Medicines (RVMD) | 1.9 | $65M | 1.6M | 39.59 | ||
| Constellation Pharmceticls I (CNST) | 1.5 | $51M | +82% | 1.8M | 28.80 | |
| Generation Bio (GBIO) | 1.4 | $46M | 1.6M | 28.35 | ||
| Dermtech Ord ord (DMTK) | 1.3 | $44M | -4% | 1.4M | 32.44 | |
| Burning Rock Biotech Sponsored Ads (BNR) | 1.3 | $44M | 1.9M | 23.10 | ||
| Adaptive Biotechnologies Cor (ADPT) | 1.2 | $42M | 713k | 59.13 | ||
| Crispr Therapeutics Namen Akt (CRSP) | 1.2 | $41M | 266k | 153.11 | ||
| Bluebird Bio (BLUE) | 1.2 | $40M | 915k | 43.27 | ||
| Adverum Biotechnologies (ADVM) | 1.2 | $40M | +32% | 3.7M | 10.84 | |
| Beigene Sponsored Adr (BGNE) | 1.1 | $39M | 150k | 258.39 | ||
| Beam Therapeutics (BEAM) | 1.1 | $38M | NEW | 460k | 81.64 | |
| Global Blood Therapeutics In (GBT) | 1.1 | $37M | +117% | 860k | 43.31 | |
| 4d Molecular Therapeutics In (FDMT) | 1.0 | $32M | NEW | 781k | 41.45 | |
| Magenta Therapeutics (MGTA) | 0.8 | $26M | 3.3M | 7.84 | ||
| Zai Lab Adr (ZLAB) | 0.8 | $26M | 190k | 135.34 | ||
| Iovance Biotherapeutics (IOVA) | 0.8 | $26M | +89% | 550k | 46.40 | |
| Alector (ALEC) | 0.7 | $25M | 1.7M | 15.13 | ||
| Allogene Therapeutics (ALLO) | 0.7 | $24M | 945k | 25.24 | ||
| 908 Devices (MASS) | 0.7 | $23M | NEW | 407k | 56.95 | |
| Taysha Gene Therapies Com Shs (TSHA) | 0.6 | $22M | 820k | 26.54 | ||
| Oric Pharmaceuticals (ORIC) | 0.6 | $20M | +139% | 602k | 33.85 | |
| Berkeley Lts (BLI) | 0.5 | $18M | 200k | 89.41 | ||
| Kronos Bio (KRON) | 0.5 | $17M | NEW | 583k | 29.87 | |
| Sangamo Biosciences (SGMO) | 0.5 | $17M | 1.1M | 15.60 | ||
| Fulcrum Therapeutics (FULC) | 0.4 | $15M | -13% | 1.2M | 11.71 | |
| Amyris Call Option (AMRS) | 0.4 | $12M | -72% | 2.0M | 6.17 | |
| Syndax Pharmaceuticals (SNDX) | 0.3 | $10M | NEW | 450k | 22.24 | |
| Black Diamond Therapeutics (BDTX) | 0.3 | $9.3M | 289k | 32.05 | ||
| Turning Point Therapeutics I (TPTX) | 0.3 | $9.1M | 75k | 121.85 | ||
| Seer Com Cl A (SEER) | 0.2 | $8.4M | NEW | 150k | 56.14 | |
| Abcellera Biologics (ABCL) | 0.2 | $8.0M | NEW | 200k | 40.24 | |
| Dyne Therapeutics (DYN) | 0.2 | $7.8M | 370k | 21.00 | ||
| Stoke Therapeutics (STOK) | 0.2 | $7.4M | 120k | 61.93 | ||
| Foghorn Therapeutics (FHTX) | 0.1 | $4.4M | NEW | 216k | 20.27 | |
| Bristol-myers Squibb Right 99/99/9999 | 0.1 | $4.3M | 6.3M | 0.69 | ||
| Codiak Biosciences (CDAK) | 0.1 | $2.5M | NEW | 77k | 32.30 | |
| C4 Therapeutics Com Stk (CCCC) | 0.0 | $1.3M | NEW | 40k | 33.12 | |
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2020 Q4 filed Feb. 16, 2021
- Casdin Capital 2020 Q3 filed Nov. 16, 2020
- Casdin Capital 2020 Q2 filed Aug. 14, 2020
- Casdin Capital 2020 Q1 filed May 15, 2020
- Casdin Capital 2019 Q4 filed Feb. 14, 2020
- Casdin Capital 2019 Q3 restated filed Jan. 3, 2020
- Casdin Capital 2019 Q3 filed Nov. 12, 2019
- Casdin Capital 2019 Q3 amended filed Nov. 12, 2019
- Casdin Capital 2019 Q2 filed Aug. 13, 2019
- Casdin Capital 2019 Q1 filed May 15, 2019
- Casdin Capital 2018 Q4 filed Feb. 13, 2019
- Casdin Capital 2018 Q3 filed Nov. 14, 2018
- Casdin Capital 2018 Q2 restated filed Aug. 20, 2018
- Casdin Capital 2018 Q2 filed Aug. 14, 2018
- Casdin Capital 2018 Q1 filed May 15, 2018
- Casdin Capital 2017 Q4 filed Feb. 14, 2018